Ten-year Follow-up of a Prospective, Randomized Trial of BT563/BB10 Versus Anti-thymocyte Globulin as Induction Therapy After Heart Transplantation

BT563/BB10 is less effective than ATG for prevention of both acute allograft rejection and allograft vasculopathy after cardiac transplantation. Clinically relevant infections or tumorgenicity were not increased with the use of ATG.